Skip to content

Magnesium sulphate in Tetanus

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN74651862
Enrollment
180
Registered
2006-09-05
Start date
2002-05-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tetanus Infections and Infestations Tetanus

Interventions

Group one - intervention group: Magnesium Sulphate intravenous (iv) infusion 0.5 - 2 g/hr. Group two - control group: Conventional treatment of intravenous diazepam (bolus 5 - 10 mg) or midazolam (inf

Sponsors

University of Oxford (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Adults with Ablett classification of tetanus severity grade three or four 2. Patient over 15 years with diagnosed tetanus 3. Tracheostomy more than six hours and not yet ventilated

Exclusion criteria

Exclusion criteria: 1. Urine output less than 1 ml/kg/hr 2. Electrocardiogram (ECG) evidence of conduction abnormalities/ischaemia 3. Serum creatinine more than 1.5 mg%

Design outcomes

Primary

MeasureTime frame
Requirement for mechanical ventilation primary outcome

Secondary

MeasureTime frame
1. Requirement for benzodiazepines, pipecuronium, morphine and verapamil (mg/kg) 2. Hourly Systolic Blood Pressure (SBP) and Heart Rate (HR) recording and mean seven day maximum SBP, HR and daily variation in SBP 3. In hospital mortality (including patients taken home to die) 4. Length of Intensive Care Unit (ICU) stay, total hospital stay and total cost of hospital stay 5. Requirement for ventilation during hospital stay 6. Daily 8 am serum Creatinine Kinase (CK) measurement 7. Urinary epinephrine and norepinephrine, measured from a 24 hour collection on day two of the study

Countries

Viet Nam

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 8, 2026